Boehringer Ingelheim Statement on Hepatitis C drug development
30th June 2014
Boehringer Ingelheim has re-evaluated its strategy in hepatitis C (HCV), and as a result the company has decided not to move forward in this therapeutic area.
The HCV treatment environment has significantly and rapidly evolved since the submission of the faldaprevir marketing applications to regulatory bodies around the world.
Read more at source article http://www.worldpharmanews.com